Solara Active Pharma Reports Q2 FY27 Financial Turnaround

Profit of Rs 28.46 crore reported for Q2 FY27; Revenue at Rs 417.34 crore.

Reader Takeaway: Revenue growth and strong profitability signal a turnaround, though managing Rs 274.16 crore in accumulated losses remains critical.

What just happened

Solara Active Pharma Sciences has announced a significant recovery for the quarter ended September 30, 2026. The company moved from a net loss of Rs 10.10 crore in Q2 FY26 to a net profit of Rs 28.46 crore in the current quarter. Total revenue grew by 33% YoY to Rs 417.34 crore. For the half-year (H1) period, the company recorded a profit of Rs 44.77 crore compared to Rs 0.42 crore in the previous year.

Why this matters

The return to profitability underscores the effectiveness of the company’s recent operational strategies. Despite reporting accumulated losses of Rs 274.16 crore as of September 2026, the management has maintained a 'going concern' assessment, citing improved margins, projected revenue growth, and expected cash flow from operations.

Corporate Actions

The company has made significant progress in its capital structure. It has successfully raised Rs 446.62 crore via a rights issue, nearly reaching its target of Rs 449.95 crore. Furthermore, the board is advancing plans to demerge the CRAMS and Polymers business. To facilitate this, the company incorporated a subsidiary, Synthix Global Pharma Solutions Limited, in April 2025.

What to track next

Investors should monitor the final deployment of the rights issue proceeds and the timeline for the proposed demerger. Sustaining operational profitability remains the key factor in addressing the company’s long-standing accumulated losses.